(P1) Design Therapeutics Inc. (Nasdaq: DSGN) reported that its gene-targeting drug, DT-216P2, achieved a 6.4-point mean improvement on a key disease severity scale in a trial of patients with Friedreich’s ataxia, a rare degenerative disease, sending a strong signal about the drug's potential to be a best-in-disease treatment. The positive data from the Phase 1/2 study links, for the first time, an increase in the deficient frataxin protein with clear clinical benefits for patients.
(P2) "These data represent an advancement for Friedreich ataxia treatment, demonstrating that DT-216P2 increased endogenous frataxin and translated biomarker observations into clinical improvements after only four weeks of treatment,” said Pratik Shah, Chief Executive Officer of Design Therapeutics. "We believe DT-216P2 has the potential to be a best-in-disease treatment for patients with FA and look forward to advancing the program toward registrational development.”
(P3) The RESTORE-FA trial evaluated weekly intravenous doses of DT-216P2 in 16 patients for four weeks. In the highest dose cohort (1 mpk), patients showed a mean improvement of 6.4 points on the modified Friedreich’s Ataxia Rating Scale (mFARS) and a 2.7-point improvement in the Upright Stability Score. Biomarker data showed dose-dependent increases in frataxin, with whole blood FXN mRNA levels rising 65 percent (p < 0.001) and protein levels increasing by 22 to 27 percent (p < 0.001) from baseline.
(P4) The results position Design Therapeutics to move toward a registrational trial, with the company planning to provide an update in the fourth quarter of 2026. This de-risks the development of DT-216P2 and boosts confidence in the company's GeneTAC® platform, which also has candidates for Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1. The positive results could attract significant investor and partnership interest in a field with high unmet need.
Design Therapeutics’ GeneTAC® (gene targeted chimera) platform is designed to create small molecules that can dial up or down the expression of specific genes. In Friedreich’s ataxia, a GAA repeat expansion in the FXN gene leads to a deficiency of the frataxin protein, causing progressive neurological and cardiac dysfunction. DT-216P2 is designed to bind to the faulty gene and restore frataxin production.
The trial data demonstrated this mechanism in action, showing a 42 percent increase in FXN mRNA in affected muscle tissue. This is a crucial proof-of-concept for the platform, showing the drug can reach target tissues and have a biological effect. The drug was generally well-tolerated, with no serious adverse events. Mild to moderate transient elevations in liver enzymes were seen in three patients, a finding the company noted is anticipated with restored mitochondrial activity, a downstream effect of frataxin increase.
The positive data provides a significant boost for Design Therapeutics in the competitive landscape for Friedreich's ataxia treatments. While other therapies exist, DT-216P2's ability to restore endogenous frataxin and show corresponding clinical improvement is a key differentiator. The trial's safety profile also appears favorable, with some adverse events noted in patients also taking omaveloxolone, another approved therapy.
For investors, the results provide a much-needed validation of the company's scientific platform. Design Therapeutics' pipeline includes other GeneTAC® programs for genetic diseases like Fuchs endothelial corneal dystrophy (DT-168), myotonic dystrophy type-1 (DT-818), and Huntington’s disease. The company's cash runway was not disclosed. The successful outcome of the RESTORE-FA trial could lead to a substantial re-rating of the company's stock and attract further investment to fund its broader pipeline.
This article is for informational purposes only and does not constitute investment advice.
